Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome
Abstract Background Chimeric antigen receptor CAR-T cell therapies have ushered in a new era of treatment for specific blood cancers, offering unparalleled efficacy in cases of treatment resistance or relapse. However, the emergence of cytokine release syndrome (CRS) as a side effect poses a challen...
Egile Nagusiak: | , , , , , , , , |
---|---|
Formatua: | Artikulua |
Hizkuntza: | English |
Argitaratua: |
BMC
2024-01-01
|
Saila: | Journal of Translational Medicine |
Gaiak: | |
Sarrera elektronikoa: | https://doi.org/10.1186/s12967-023-04779-z |